18氟代脱氧葡萄糖PET/CT评估弥漫大B细胞淋巴瘤患者动脉炎症进展的作用研究

doi:10.3969/j.issn.1673-5765.2025.02.010

摘要/Abstract

摘要： 目的通过PET/CT评估弥漫大B细胞淋巴瘤（diffuse large B-cell lymphoma，DLBCL）患者化疗中期较化疗前动脉摄取18氟代脱氧葡萄糖（18F-fluorodeoxyglucose，18F-FDG）水平的变化，反映患者化疗过程中动脉炎症的变化情况。
方法回顾性连续纳入2021年1月—2023年1月于山东第二医科大学第一附属医院诊治的DLBCL患者作为研究对象。所有患者均在化疗前及化疗中期进行了18F-FDG PET/CT检查。使用最大靶本底比（maximum target-to-background ratio，TBRmax）及平均靶本底比（mean target-to-background ratio，TBRmean）评估颈动脉和主动脉化疗前、化疗中期的动脉炎症水平。颈动脉评估部位包括颈动脉整体测量段（whole carotid artery，CA-WH）和颈动脉最严重病变段（most-diseased segment of the carotid，CA-MDS）；主动脉评估部位包括升主动脉、主动脉弓、胸主动脉和腹主动脉。分别比较整体患者化疗中期和化疗前左、右侧CA-WH-TBRmax、CA-WH-TBRmean、CA-MDS-TBRmax和CA-MDS-TBRmean，以及主动脉各部位的TBRmax和TBRmean的差异。根据超声检查的颈动脉粥样硬化斑块情况，将患者分为不稳定斑块组、稳定斑块组及无斑块组，分别比较3组患者左、右两侧CA-WH-TBRmax和CA-WH-TBRmean的Δ靶本底比（target-to-background ratio，TBR）（化疗中期TBR-化疗前TBR），评估3组化疗期间颈动脉炎症水平变化程度的差异。
结果共纳入85例DLBCL患者，其中不稳定斑块组26例（30.6%），稳定斑块组24例（28.2%），无斑块组35例（41.2%）。整体患者中，化疗中期双侧CA-WH-TBRmax（左侧P=0.015，右侧P=0.034）、CA-MDS-TBRmax（左侧P＜0.001，右侧P=0.041）、CA-MDS-TBRmean（左侧P=0.029，右侧P=0.008）、升主动脉TBRmax（P=0.010）较化疗前显著增高，差异有统计学意义。不稳定斑块组左侧CA-WH-ΔTBRmax较无斑块组（P=0.005）更高，差异具有统计学意义；不稳定斑块组左侧CA-WH-ΔTBRmean较无斑块组（P=0.003）、稳定斑块组（P=0.025）更高，差异均有统计学意义。
结论化疗可加速DLBCL患者双侧颈动脉及升主动脉炎症的进展，PET/CT技术能够识别化疗相关动脉炎症的演变，从而为临床早期干预动脉粥样硬化提供依据。

文章导读： 本研究针对DLBCL患者这一特殊群体，基于反映动脉病理学变化的18F-FDG PET/CT检查，发现化疗期间患者的局部动脉炎症反应逐渐加重，且这种变化在不同动脉粥样硬化程度的患者人群以及左右侧颈动脉之间存在差异。

关键词: 血管炎症; 动脉粥样硬化; 心脑血管疾病; 正电子发射断层成像; 脱氧葡萄糖

Abstract: Objective To evaluate the changes in arterial uptake of 18F-fluorodeoxyglucose (18F-FDG) before and at mid-chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL) through PET/CT, reflecting the changes in arterial inflammation during the chemotherapy process.
Methods Patients with DLBCL who were diagnosed and treated at the First Affiliated Hospital of Shandong Second Medical University between January 2021 and January 2023 were retrospectively and consecutively included in the study. All patients underwent 18F-FDG PET/CT examinations before and at mid-chemotherapy. The maximum target-to-background ratio (TBRmax) and mean target-to-background ratio (TBRmean) were used to evaluate the inflammation levels in the carotid and aortic arteries before and at mid-chemotherapy. The carotid artery evaluation sites included the whole carotid artery (CA-WH) and the most-diseased segment of the carotid (CA-MDS). The aortic artery evaluation sites included the ascending aorta, aortic arch, thoracic aorta, and abdominal aorta. The differences in CA-WH-TBRmax, CA-WH-TBRmean, CA-MDS-TBRmax, and CA-MDS-TBRmean of the left and right carotid arteries in the overall patients before and at mid-chemotherapy, as well as the differences in TBRmax and TBRmean of various parts of the aorta, were compared, respectively. Based on the results of ultrasonic examinations of carotid atherosclerotic plaques, patients were classified into three groups: the unstable plaque group, the stable plaque group, and the no plaque group. The changes in target-to-background ratio (ΔTBR) (mid-chemotherapy TBR-pre-chemotherapy TBR) of the left and right CA-WH-TBRmax and CA-WH-TBRmean among the three groups were compared respectively to evaluate the differences in the degree of carotid inflammation changes during chemotherapy.
Results A total of 85 patients with DLBCL were included in the study, including 26 patients (30.6%) in the unstable plaque group, 24 patients (28.2%) in the stable plaque group, and 35 patients (41.2%) in the no plaque group. In the overall patients, the bilateral CA-WH-TBRmax (left side P=0.015, right side P=0.034), CA-MDS-TBRmax (left side P<0.001, right side P=0.041), CA-MDS-TBRmean (left side P=0.029, right side P=0.008), and ascending aorta TBRmax (P=0.010) were significantly higher at mid-chemotherapy than pre-chemotherapy, with statistically significant differences. In the unstable plaque group, the left CA-WH-ΔTBRmax value was higher than that in the no plaque group (P=0.005), with a statistically significant difference. Additionally, the left CA-WH-ΔTBRmean in the unstable plaque group was higher than that in both the no plaque group (P=0.003) and the stable plaque group (P=0.025), with statistically significant differences.
Conclusions Chemotherapy can accelerate the progression of inflammation in bilateral carotid arteries and ascending aorta of patients with DLBCL. During the tumor follow-up, PET/CT technology can early identify the evolution of chemotherapy-related arterial inflammation, thus providing a basis for early clinical intervention in atherosclerosis.

Key words: Vascular inflammation; Atherosclerosis; Cardio-cerebrovascular disease; Positron emission tomography; Deoxyglucose

中图分类号:

范萍, 李爱媛, 赵喆, 李现军, 战同霞, 谢海. ¹⁸氟代脱氧葡萄糖PET/CT评估弥漫大B细胞淋巴瘤患者动脉炎症进展的作用研究[J]. 中国卒中杂志, 2025, 20(2): 199-207.

FAN Ping, LI Aiyuan, ZHAO Zhe, LI Xianjun, ZHAN Tongxia, XIE Hai. A Study of the Role of ¹⁸F-Fluorodeoxyglucose PET/CT in Assessing the Progression of Arterial Inflammation in Patients with Diffuse Large B-Cell Lymphoma[J]. Chinese Journal of Stroke, 2025, 20(2): 199-207.

参考文献

[1] SUNG H，FERLAY J，SIEGEL R L，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71（3）：209-249.
[2] ALLEMANI C，MATSUDA T，DI CARLO V，et al. Global surveillance of trends in cancer survival 2000—2014（CONCORD-3）：analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet，2018，391（10125）：1023-1075.
[3] STURGEON K M，DENG L，BLUETHMANN S M，et al. A population-based study of cardiovascular disease mortality risk in US cancer patients[J]. Eur Heart J，2019，40（48）：3889-3897.
[4] ZAORSKY N G，CHURILLA T M，EGLESTON B L，et al. Causes of death among cancer patients[J]. Ann Oncol，2017，28（2）：400-407.
[5] ZHANG Y Y，CHAN D K Y，CORDATO D，et al. Stroke risk factor，pattern and outcome in patients with cancer[J]. Acta Neurol Scand，2006，114（6）：378-383.
[6] KOENE R J，PRIZMENT A E，BLAES A，et al. Shared risk factors in cardiovascular disease and cancer[J]. Circulation，2016，133（11）：1104-1114.
[7] TAJIRI K，AONUMA K，SEKINE I. Cardiovascular toxic effects of targeted cancer therapy[J]. Jpn J Clin Oncol，2017，47（9）：779-785.
[8] 杨启舟，付睿，王莉莉. 肿瘤相关脑梗死发病机制的研究进展[J]. 中国卒中杂志，2021，16（2）：124-129.
YANG Q Z，FU R，WANG L L. Pathogenesis of cancer-associated ischemic stroke[J]. Chin J Stroke，2021，16（2）：124-129.
[9] HERRMANN J. Vascular toxic effects of cancer therapies[J]. Nat Rev Cardiol，2020，17（8）：503-522.
[10] SHIMIZU N，NGAYAMA D，WATANABE Y，et al. Rituximab，cyclophosphamide，doxorubicin，vincristine，and prednisolone（R-CHOP）therapy increases carotid intima-media thickness and plaque score with von Willebrand factor activity elevation in patients with malignant lymphoma[J]. J Chemother，2022，34（4）：258-263.
[11] 中国医疗保健国际交流促进会肿瘤内科学分会，中国抗癌协会淋巴瘤专业委员会，中国医师协会肿瘤医师分会. 中国淋巴瘤治疗指南（2023年版）[J]. 中国肿瘤临床与康复，2023，30（1）：2-39.
Medical Oncology Branch of Chinese International Exchange and Promotion Association for Medical and Healthcare，China Anti-cancer Association Lymphoma Committee，Chinese Association for Clinical Oncologists. Clinical practice guideline for lymphoma in China（2023 version）[J]. Chin J Clin Oncol Rehabil，2023，30（1）：2-39.
[12] JEZOVNIK M K，ZIDAR N，LEZAIC L，et al. Identification of inflamed atherosclerotic lesions in vivo using PET-CT[J]. Inflammation，2014，37（2）：426-434.
[13] COCKER M S，SPENCE J D，HAMMOND R，et al. [18F]-fluorodeoxyglucose PET/CT imaging as a marker of carotid plaque inflammation：comparison to immunohistology and relationship to acuity of events[J/OL]. Int J Cardiol，2018，271：378-386[2024-04-14]. https://doi.org/10.1016/j.ijcard.2018.05.057.
[14] BLANKSTEIN R，LIBBY P，BHATT D L. Arterial inflammation：the heat before the storm[J]. J Am Coll Cardiol，2019，73（12）：1383-1385.
[15] HENEIN M Y，VANCHERI S，LONGO G，et al. The role of inflammation in cardiovascular disease[J/OL]. Int J Mol Sci，2022，23（21）：12906[2024-04-14]. https://doi.org/10.3390/ijms232112906.
[16] 中华医学会核医学分会. 淋巴瘤18F-FDG PET/CT及PET/MR显像临床应用指南（2021版）[J]. 中华核医学与分子影像杂志，2021，41（3）：161-169.
Chinese Society of Nuclear Medicine. Clinical practice guideline of 18F-FDG PET/CT and PET/MR in lymphoma（2021 edition）[J]. Chin J Nucl Med Mol Imaging，2021，41（3）：161-169.
[17] YOON H E，KIM Y，KIM S D，et al. A pilot trial to examine the changes in carotid arterial inflammation in renal transplant recipients as assessed by 18F-fluorodeoxyglucose（18F-FDG）positron emission tomography computed tomography（PET/CT）[J/OL]. Ann Transplant，2018，23：412-421[2024-04-14]. https://doi.org/10.12659/AOT.909212.
[18] 国家卫生计生委脑卒中防治工程委员会. 中国脑卒中血管超声检查指导规范[J]. 中华医学超声杂志（电子版），2015，12（8）：599-610.
Stroke Prevention Project Committee，National Health Commission. Chinese guidelines for vascular ultrasound examination of stroke[J]. Chin J Med Ultrasound（Electronic Edition），2015，12（8）：599-610.
[19] 李文兰，朱叶锋，冉海涛. 超声诊断颈动脉易损斑块的研究进展[J]. 中国介入影像与治疗学，2018，15（1）：55-58.
LI W L，ZHU Y F，RAN H T. Research progresses of ultrasound in diagnosis of carotid artery vulnerable plaque[J]. Chin J Interv Imaging Ther，2018，15（1）：55-58.
[20] CAMPIA U. Vascular effects of cancer treatments[J]. Vasc Med，2020，25（3）：226-234.
[21] TOTZECK M，AIDE N，BAUERSACHS J，et al. Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity：prospects and proposal of use by the European Association of Nuclear Medicine（EANM）[J]. Eur J Nucl Med Mol Imaging，2023，50（3）：792-812.
[22] RUDD J H，MYERS K S，BANSILAL S，et al. Atherosclerosis inflammation imaging with 18F-FDG PET：carotid，iliac，and femoral uptake reproducibility，quantification methods，and recommendations[J]. J Nucl Med，2008，49（6）：871-878.
[23] FIFER K M，QADIR S，SUBRAMANIAN S，et al. Positron emission tomography measurement of periodontal 18F-fluorodeoxyglucose uptake is associated with histologically determined carotid plaque inflammation[J]. J Am Coll Cardiol，2011，57（8）：971-976.
[24] MOON S H，CHO Y S，NOH T S，et al. Carotid FDG uptake improves prediction of future cardiovascular events in asymptomatic individuals[J]. JACC Cardiovasc Imaging，2015，8（8）：949-956.
[25] CHEN X G，ZHENG Y R，TATSUOKA C，et al. Chemoradiotherapy-related carotid artery inflammation in head and neck cancer patients quantified by [18F] FDG PET/CT[J/OL]. Oral Oncol，2019，93：101-106[2024-04-14]. https://doi.org/10.1016/j.oraloncology.2019.04.008.
[26] LIN R L，YU J，TIAN A J，et al. Time-related vascular inflammatory response to COVID-19 assessed by 18F-FDG PET/CT in follow-up tumor patients[J/OL]. J Inflamm Res，2023，16：3109-3117[2024-04-14]. https://doi.org/10.2147/JIR.S415288.
[27] LAWAL I O，ORUNMUYI A T，POPOOLA G O，et al. FDG PET/CT for evaluating systemic arterial inflammation induced by anthracycline-based chemotherapy of Hodgkin lymphoma：a retrospective cohort study[J/OL]. Medicine（Baltimore），2020，99（48）：e23259[2024-04-14]. https://doi.org/10.1097/MD.0000000000023259.
[28] SELWANESS M，VAN DEN BOUWHUIJSEN Q，VAN ONKELEN R S，et al. Atherosclerotic plaque in the left carotid artery is more vulnerable than in the right[J]. Stroke，2014，45（11）：3226-3230.
[29] SHAO S，SHI H L，WANG G B，et al. Differences in left and right carotid plaque vulnerability in patients with bilateral carotid plaques：a CARE-Ⅱ study[J]. Stroke Vasc Neurol，2023，8（4）：284-291.
[30] SYED M B，FLETCHER A J，FORSYTHE R O，et al. Emerging techniques in atherosclerosis imaging[J/OL]. Br J Radiol，2019，92（1103）：20180309[2024-04-14]. https://doi.org/10.1259/bjr.20180309.
[31] HUBALEWSKA-DYDEJCZYK A，STOMPÓR T，KALEMBKIEWICZ M，et al. Identification of inflamed atherosclerotic plaque using 123I-labeled interleukin-2 scintigraphy in high-risk peritoneal dialysis patients：a pilot study[J]. Perit Dial Int，2009，29（5）：568-574.
[32] SCHWARTZ S M，GALIS Z S，ROSENFELD M E，et al. Plaque rupture in humans and mice[J]. Arterioscler Thromb Vasc Biol，2007，27（4）：705-713.
[33] FIGUEROA A L，ABDELBAKY A，TRUONG Q A，et al. Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events[J]. JACC Cardiovasc Imaging，2013，6（12）：1250-1259.
[34] AYUBCHA C，AMANULLAH A，PATEL K H，et al. Stroke and molecular imaging：a focus on FDG-PET[J]. Am J Nucl Med Mol Imaging，2023，13（2）：51-63.
[35] BUCERIUS J，HYAFIL F，VERBERNE H J，et al. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine（EANM）on PET imaging of atherosclerosis[J]. Eur J Nucl Med Mol Imaging，2016，43（4）：780-792.
[36] TAWAKOL A，FAYAD Z A，MOGG R，et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation：results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study[J]. J Am Coll Cardiol，2013，62（10）：909-917.
[37] LEE Y B，CHOI K M. Diet-modulated lipoprotein metabolism and vascular inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography[J/OL]. Nutrients，2018，10（10）：1382[2024-04-14]. https://doi.org/10.3390/nu10101382.

¹⁸氟代脱氧葡萄糖PET/CT评估弥漫大B细胞淋巴瘤患者动脉炎症进展的作用研究

A Study of the Role of ¹⁸F-Fluorodeoxyglucose PET/CT in Assessing the Progression of Arterial Inflammation in Patients with Diffuse Large B-Cell Lymphoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	符鹏程, 曹黎明, 朱佳倩, 赵桂玉, 徐格林. 大动脉粥样硬化性缺血性卒中再灌注治疗的研究进展[J]. 中国卒中杂志, 2024, 19(9): 1004-1011.
[2]	中国卒中学会医疗质量管理与促进分会, 《中英文标准化动脉粥样硬化性脑血管病术语中国专家共识》编写组. 中英文标准化动脉粥样硬化性脑血管病术语中国专家共识 [J]. 中国卒中杂志, 2024, 19(8): 973-977.
[3]	李彦江, 刘彤晖, 田惠, 孙岩, 张勇. 药物涂层球囊与普通球囊血管成形术治疗症状性颅内动脉粥样硬化性狭窄的安全性和预后对比研究 [J]. 中国卒中杂志, 2024, 19(7): 803-808.
[4]	尚媛媛, 杜正静, 陈静怡, 彭波, 龙杰琦. 心脑血管疾病与气象因素关系预测模型的建立与评估[J]. 中国卒中杂志, 2024, 19(6): 632-639.
[5]	赵晨阳, 李进, 李东野, 乔会昱, 赵锡海, 周丹. 颅内动脉与颈动脉并存斑块分布特征对缺血性卒中复发风险的预测价值研究[J]. 中国卒中杂志, 2024, 19(6): 647-654.
[6]	李爱媛, 范萍, 李现军, 赵喆, 战同霞, 谢海. ¹⁸氟代脱氧葡萄糖PET/CT对活动性恶性肿瘤患者发生急性缺血性卒中预测作用研究[J]. 中国卒中杂志, 2024, 19(2): 150-157.
[7]	王艳玲, 王雪梅. 普罗布考联合阿托伐他汀治疗多发脑血管狭窄合并主动脉弓溃疡斑块病例报道[J]. 中国卒中杂志, 2024, 19(2): 202-206.
[8]	王伊龙, 陈玮琪, 刘欣如, 王文志, 王永刚, 王婷婷, 王蓬莲, 刘改芬, 江滨, 许予明, 许玉园, 许杰, 孙冬玲, 孙海欣, 李子孝, 李姝雅, 杨沫, 杨晓萌, 杨营营, 周梦圆, 郑华光, 宗黎霞, 单舒乙, 赵璟妍, 茹小娟, 姜勇, 秦海强, 贾茜, 高远, 梅延亮, 曹勇, 盖思齐, 焦玉明, 谢雪微, 潘岳松, 中国卒中学会中国脑血管病临床管理指南撰写工作委员会. 中国脑血管病临床管理指南（第2版）（节选）——第3章脑血管病高危人群管理[J]. 中国卒中杂志, 2023, 18(8): 898-909.
[9]	司倩倩, 程安琪, 范晓媛, 张晓倩, 李明利, 冯逢, 刘彩燕, 徐蔚海. 症状性颅内动脉粥样硬化性狭窄患者的认知功能及脑结构改变[J]. 中国卒中杂志, 2023, 18(11): 1228-1237.
[10]	梁佳, 康慧斌, 李葆青, 隋滨滨. 青年颅内动脉狭窄患者高分辨率磁共振血管壁成像的影像特征[J]. 中国卒中杂志, 2023, 18(11): 1255-1261.
[11]	王璐, 王健. 穿支动脉粥样硬化病患者早期神经功能恶化的研究进展[J]. 中国卒中杂志, 2023, 18(10): 1191-1195.
[12]	于文龙, 白茹玉, 禹延雪, 郭霞, 吴丽娥. 内蒙古包头地区40岁及以上人群抗血小板聚集类药物使用现状及影响因素的真实世界研究[J]. 中国卒中杂志, 2023, 18(06): 651-659.
[13]	中国卒中学会, 中国卒中学会神经介入分会, 中华预防医学会卒中预防与控制专业委员会介入学组. 急性缺血性卒中血管内治疗中国指南2023[J]. 中国卒中杂志, 2023, 18(06): 684-711.
[14]	瓮佳旭, 周宏宇, 李子孝. DNA甲基化与高同型半胱氨酸血症[J]. 中国卒中杂志, 2023, 18(04): 404-409.
[15]	司倩倩, 程安琪, 范晓媛, 张晓倩, 李明利, 冯逢, 刘彩燕, 徐蔚海. 颅内动脉粥样硬化性狭窄与认知功能的关系研究[J]. 中国卒中杂志, 2023, 18(04): 418-427.